HOME > Chiesi España > Chiesi Spain News
 
Chiesi Group receives the European Marketing Authorisation for Lamzede® (velmanase alfa)
  Lamzede® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha‑mannosidosis (AM). AM...
1/11
Chiesi Spain and Richi Entrepreneurs launch the II call to choose the best health startup
2/11
-
3/11
ARCHIVE NEWS
-
-
-
New study published in The Lancet shows Trimbow® superiority over Ultibro® Breezhaler®
Chiesi Group receives positive opinion from CHMP for Lamzede®, the First Therapy For Alpha Mannosidosis
"Internal entrepreneurs are key to the evolution of companies"
CHIESI LEADS THE RANKING OF ITALIAN COMPANIES THAT INVEST IN R & D
Balanced nutrition helps prevent decompensation in COPD
Reducing the risk of long-term rejection is the great challenge pending in liver and kidney transplants
-
-
-
"TRANSPLANTATION IN ACTION" ALLOWS MORE THAN 70 MIR OF NEPHROLOGY TO BE FORMED USING NEW GAMIFICATION TECHNIQUES
-
CHIESI ENTERS INTO AN EXCLUSIVE EX-US PARTNERSHIP WITH PROTALIX BIOTHERAPEUTICS FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRX-102 (PEGUNIGALSIDASE ALFA) FOR THE TREATMENT OF FABRY DISEASE
-
-
Chiesi Group receives the European Marketing Authorisation for Trimbow® (ICS/LABA/LAMA)
Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin inhalation solution) in Europe, Middle East and Africa (EMEA) Regions from Horizon Phar
-
Respiration Day 2017
"Between 10-15% of cases of asthma in adults can have their origin in the workplace"
-
-
-
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE
-
-
Chiesi and Molecular Warehouse join forces to create innovative diagnostic tool for transplant patients
Chiesi grants the startup New Born Solutions to participate in the immersion program of Richi Social Entrepreneurs in Boston
Published the second issue of the NewsRARE magazine on Patient Records and Orphan Drugs
-
-
-
NeumoChiesi 2016
Chiesi signs a collaboration agreement with DyCare to measure tremors in patients with transplants
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study, which shows one year data on the superior efficacy of the first extrafine fixed ICS/LABA/LAMA triple combination for COPD treatment compared with standard therapy
-
-
-
Beatriz Vila, Director of People of Chiesi has been awarded in the HR Director category
-